Navigation Links
NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
Date:3/19/2009

Broad Label Indicated for Peripheral Neuropathic Pain in Non-Diabetic Adults

Conference Call Scheduled Friday, March 20 at 9am ET

SAN MATEO, Calif., March 19 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Qutenza(TM) (formerly NGX-4010), for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.

Qutenza is a high-concentration capsaicin dermal patch designed to provide rapid, localized and sustained relief from peripheral neuropathic pain. The CHMP's positive recommendation will be evaluated by the European Commission, and a decision on marketing authorization is expected in the next 60 to 90 days.

Anthony DiTonno, President and CEO, commented, "The CHMP's positive recommendation for approval of Qutenza in the European Union provides significant validation for both Qutenza and NeurogesX. Since its founding in 2000, NeurogesX has been dedicated to bringing Qutenza to market for patients with neuropathic pain, a patient population that is largely unsatisfied with existing approved therapies. We are excited to be on the doorstep of potential commercialization. In preparation for a potentially positive final decision by the European Commission, we will be focused on finalizing a relationship with a commercial partner in Europe over the next few months."

Dr. Jeffrey Tobias, Chief Medical Officer, commented, "We believe that, if approved, Qutenza may become an important addition to the treatment options currently ava
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
2. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
3. NeurogesX Reports Third Quarter 2008 Results
4. NeurogesX to Report Third Quarter 2008 Financial Results
5. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
6. NeurogesX Responds to EMEAs Day 120 Questions
7. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
8. NeurogesX Reports Second Quarter 2008 Results
9. NeurogesX to Report Second Quarter 2008 Financial Results
10. NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998
11. NeurogesX to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
(Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Narcotic and Pain-Management Market ... ... American Oriental,Bioengineering, Inc. (NYSE: AOB ), a leading marketer, ... China,Aoxing Pharmaceutical Company, Inc. (OTC Bulletin Board: CAXG) ("China,Aoxing"), a ...
... CryoPort, Inc. (OTC,Bulletin Board: CYRX) (http://www.CryoPort.com ... personal profile on MyWallst.net available at, http://www.wallst.net . ... on which investors can comment, and links to ... Mywallst.net at, http://my.wallst.net/profile.php?ID=19849 . Stay updated about ...
... In Vivo ... Imaging-, HOPKINTON, ... introduced Bioware(R) Ultra cell lines,a range of ultra bright light producing tumor ... are,10 to 100 times brighter than cell lines created using traditional methods,which ...
Cached Biology Technology:American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance 2American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance 3American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance 4CryoPort Creates Personal Wall on Wallst.net's Financial Social Community, my.wallst.net 2Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 2Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 3
(Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
(Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
(Date:11/21/2014)... DALLAS , November 18, 2014 ... Security Systems Market by Systems (Video, RFID, Access Control, ... (SEZ, Factories, Hotels, Banks, Government), Component Service Geography - ... Security Systems Market is projected to be around $25 ... Billion by 2020, growing at a CAGR of 8.69%. ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... 2009) Brief but personal intervention reduces drinking among ... The University of Texas School of Public Health. Results ... issue of the Journal of Consulting and Clinical ... UT School of Public Health Dallas Regional Campus, led ...
... Jan. 30, 2009 Screening a chemical library of ... identified two new classes that can be used to ... many types of cancer and degenerative diseases. "The ... cellular pathway represents an important step in developing therapeutic ...
... An experiment to study the effects of naturally deposited ... key piece of the puzzle surrounding iron,s role in ... research, conducted by an international team led by Raymond ... Matthew Charette, a marine chemist at the Woods Hole ...
Cached Biology News:Intervention method reduces binge drinking 2UT Southwestern researchers disrupt biochemical system involved in cancer, degenerative disease 2Ocean islands fuel productivity and carbon sequestration through natural iron fertilization 2Ocean islands fuel productivity and carbon sequestration through natural iron fertilization 3
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
ELISpot kit for human Granzyme B. Kits contain PVDF plates, capture & detection antibodies, streptavidin-ALP, BSA, Skimmed dry milk, BCIP/NTB substrate, and wash buffer...
1 unit is sufficient for 1 caspase activity assay....
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
Biology Products: